Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Differential Protein Expression Profile Between CD20 Positive and Negative Cells of the NCI-H929 Cell Line

  • Geng, Chuan-Ying (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Liu, Nian (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Yang, Guang-Zhong (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Liu, Ai-Jun (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Leng, Yun (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Wang, Hui-Juan (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Li, Li-Hong (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Wu, Yin (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Li, Yan-Chen (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University) ;
  • Chen, Wen-Ming (Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

At present, multiple myeloma (MM) remains an incurable disease and cologenic cells may be responsible for disease relapse. It has been proposed that CD20+/CD138- NCI-H929 cells could be hallmarks of MM clonogenic cells. Here, the immunology phenotype of NCI-H929 cells is described. Only a small population of CD20+/CD138- cells (<1%) was found in the NCI-H929 cell line, but CD20+/CD138- cells were not detected. We found that CD20+/CD138+ cells were able to exhibit cologenic capacity by colony formation assay and continuous passage culture. Proteins were analyzed by 1D-SDS-PAGE and TMT based quantitative differential liquid chromatography tandem mass spectrometry (LC-MS/MS). 1,082 non-redundant proteins were identified, 658 of which were differentially expressed with at least a 1.5-fold difference. 205 proteins in CD20+ cells were expressed at higher levels and 453 proteins were at lower levels compared with CD20- cells. Most proteins had catalytic and binding activity and mainly participated in metabolic processes, cell communication and molecular transport. These results proved that there are different biological features and protein expression profile between CD20+ and CD20- cells in the NCI-H929 cell line.

Keywords

References

  1. Brennan SK, Matsui W (2009). Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl), 87, 1079-85. https://doi.org/10.1007/s00109-009-0531-7
  2. Chiron D, Surget S, Maiga S, et al (2012). The peripheral CD138+ population but not the CD138-population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol, 156, 679-83. https://doi.org/10.1111/j.1365-2141.2011.08904.x
  3. Hong D, Chen HX, Yu HQ, et al (2011). Quantitative proteomic analysis of dexamethasone-induced effects on osteoblast differentiation, proliferation, and apoptosis in MC3T3-E1 cells using SILAC. Osteoporos Int, 22, 2175-86. https://doi.org/10.1007/s00198-010-1434-8
  4. Hosen N, Matsuoka Y, Kishida S, et al (2012). CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia, 26, 2135-41. https://doi.org/10.1038/leu.2012.80
  5. Huff CA, Matsui W (2008). Multiple myeloma cancer stem cells. J Clin Oncol, 26, 2895-900. https://doi.org/10.1200/JCO.2007.15.8428
  6. Jakubikova J, Adamia S, Kost-Alimova M, et al (2011). Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood, 117, 4409-19. https://doi.org/10.1182/blood-2010-02-267344
  7. Khan MM, Mori M, Sakauchi F, et al (2006). Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev, 7, 575-81.
  8. Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78, 21-33. https://doi.org/10.4065/78.1.21
  9. Kyle RA, Rajkumar SV(2008). Multiple myeloma. Blood, 111, 2962-72. https://doi.org/10.1182/blood-2007-10-078022
  10. Matsui W, Huff CA, Wang Q, et al (2004). Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332-6. https://doi.org/10.1182/blood-2003-09-3064
  11. Matsui W, Wang Q, Barber JP, et al (2008). Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res, 68, 190-7. https://doi.org/10.1158/0008-5472.CAN-07-3096
  12. Paino T, Ocio EM, Paiva B, et al (2012). CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica, 97, 1110-4. https://doi.org/10.3324/haematol.2011.057372
  13. Pilarski LM, Hipperson G, Seeberger K, et al (2000). Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood, 95, 1056-65.
  14. Pilarski LM, Seeberger K, Coupland RW, et al (2002). Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol, 30, 221-8. https://doi.org/10.1016/S0301-472X(01)00788-3
  15. Raab MS, Podar K, Breitkreutz I, et al (2009). Multiple myeloma. Lancet, 374, 324-39. https://doi.org/10.1016/S0140-6736(09)60221-X
  16. Rajkumar SV (2011). Multiple myeloma: (2011) update on diagnosis, risk-stratification, and management. Am J Hematol, 86, 57-65. https://doi.org/10.1002/ajh.21913
  17. Yaccoby S, Barlogie B, Epstein J (1998). Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood, 92, 2908-13.
  18. Yaccoby S, Epstein J (1999). The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood, 94, 3576-82.
  19. Zhang Z, Zhang L, Hua Y, et al (2010). Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines. BMC Cancer, 10, 206-14. https://doi.org/10.1186/1471-2407-10-206